AbbVie Defeats Humira Patent Cliff to Resume Growth

Key Moments

AbbVie Outperforms as Peers Struggle With Patent and Revenue Pressures

For an extended period, investors viewed the loss of exclusivity on Humira as an unavoidable breaking point for AbbVie Inc (NYSE:ABBV), the company behind what had been described as the best-selling drug in history. Many on Wall Street anticipated several years of earnings pressure and some conservative shareholders stepped aside accordingly. Contrary to those concerns, AbbVie shares have climbed 16.8% since InvestingPro’s ProPicks AI models added the name on August 1, including a 6.0% advance over the past month even as the broader equity market moved lower.

This performance divergence underscores where capital in the pharmaceutical sector is gravitating for perceived stability. While companies such as Pfizer (NYSE:PFE) work through declines in post-pandemic vaccine revenue and Bristol-Myers Squibb (NYSE:BMY) faces impending patent expirations, AbbVie has executed on something rarely seen around a major patent cliff: introducing commercial products capable of offsetting the revenue erosion before the legacy portfolio fully recedes.

Identifying situations where a company’s development and commercialization progress outstrips prevailing market skepticism is a key objective of InvestingPro’s ProPicks AI models. AbbVie remains a component of both the Beat the S&P 500 and Healthcare Heroes strategies. Within Healthcare Heroes’ active November portfolio, AbbVie is positioned alongside a concentrated set of resilient healthcare businesses, including a commercial HIV and oncology therapeutics leader, a specialty healthcare operator in the midst of a turnaround, and a supplier of precision laboratory instruments.

Transition Beyond Humira: New Immunology Leaders Step In

Third-quarter results illustrate how quickly AbbVie’s transition from Humira has advanced. The company reported adjusted earnings per share of $3.82, exceeding consensus expectations of $3.74, on total revenue of $17.4 billion. That represented 10.5% operational sales growth. Even as global Humira sales fell another 30.6% to $683 million, management raised its full-year outlook, now expecting adjusted EPS between $13.95 and $13.99 and revenue of roughly $67.8 billion.

The primary engine behind this shift has been AbbVie’s next-generation immunology portfolio. Skyrizi generated revenue of nearly $5.8 billion in the quarter, up 22.9% year over year, while Rinvoq produced $2.7 billion, a 24.3% increase. Management’s updated guidance calls for full-year sales of $21.8 billion for Skyrizi and $10.3 billion for Rinvoq. A key competitive factor is Skyrizi’s ongoing capture of approximately half of all new patient starts across psoriasis and inflammatory bowel disease, which is helping to establish a multiyear competitive position.

Neuroscience Expansion Adds a Second Growth Pillar

Beyond immunology, AbbVie’s neuroscience operations have developed into a more substantial contributor. Segment revenue advanced 19.5% year over year to nearly $3.4 billion, aided by broader adoption of Vraylar and Botox Therapeutic. In response to this momentum, management raised its full-year neuroscience revenue target to $13 billion. Across the broader portfolio, nine commercial therapies posted double-digit sales growth during the quarter, reinforcing the company’s diversified growth base.

Cash Generation, Dividends, and Valuation Metrics

AbbVie’s operational execution has translated into meaningful cash generation. Over the first nine months of 2026, the company produced approximately $14 billion in operating cash flow. This has allowed AbbVie to self-fund targeted bolt-on acquisitions such as Apogee Therapeutics while also supporting a 5.2% increase in its quarterly dividend to $1.82.

Including its history as part of Abbott Laboratories, AbbVie has now delivered 52 consecutive years of dividend increases, currently offering a yield of 2.5%. For income-oriented investors, this track record highlights the company’s emphasis on shareholder returns alongside pipeline and business development investments.

Valuation indicators point to an earnings profile that is expected to improve. Although trailing earnings result in a multiple of 49.5 times, AbbVie trades at about 21.0 times forward earnings estimates, with a PEG ratio of 0.15. According to consensus analyst estimates compiled on InvestingPro, EPS is projected to rise from $14.04 this year to $16.25 in 2027. The median analyst price target of $306.42 compares with recent trading levels near $291.31, suggesting capacity for valuation multiple expansion if execution remains on track.